| SFDA Approved Use |
Metastatic Colorectal Cancer (mCRC)
• Bevacizumab in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC). • Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use: Bevacizumab is not indicated for adjuvant treatment of colon cancer. First-Line Non-Squamous Non–Small Cell Lung Cancer (NSCLC) • Bevacizumab in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer (NSCLC). Recurrent Glioblastoma (GBM) • Bevacizumab is indicated for the treatment of recurrent glioblastoma (GBM) in adults. Metastatic Renal Cell Carcinoma (mRCC) • Bevacizumab in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC). Persistent, Recurrent, or Metastatic Cervical Cancer • Bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer • Bevacizumab in combination with carboplatin and paclitaxel, followed by Acura® as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. • Bevacizumab in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. • Bevacizumab in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Acura® as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Hepatocellular Carcinoma (HCC) • Bevacizumab in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.